ReviewF1000Research2020
Hepatocellular carcinoma: recent advances and emerging medical therapies.
Review in F1000Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- The association between antibiotic use and outcomes of HCC patients treated with immune checkpoint inhibitors.Frontiers in immunology · 2022Pooled it
- ADCK1 Regulates Mitochondrial Bioenergetics in Hepatocellular Carcinoma In Vitro.International journal of molecular sciences · 2026Article
- Anatomy of the right portal vein and right hepatic vein for anatomical minimally invasive liver resection.iLIVER · 2026Article
- LAPTM4B and MMP9 Immunohistochemical Expression in Hepatocellular Carcinoma: Relation to Clinicopathological Features and Prognostic Implications in Egyptian Patients.Iranian journal of pathology · 2026Article
- Correlation between dual-time-pointQuantitative imaging in medicine and surgery · 2025Article
- Relationship between skeletal muscle mass and prognosis in patients with liver cancer receiving targeted therapy: A meta-analysis.World journal of clinical oncology · 2025Article
- Review
- Survival Benefit of Synchronous Lenvatinib Combined PD-1 Inhibitors for Advanced Hepatocellular Carcinoma Beyond Oligometastasis.ImmunoTargets and therapy · 2024Article
- Lipid polymer hybrid nanoparticles: a custom-tailored next-generation approach for cancer therapeutics.Molecular cancer · 2023Review
- Cell-Free DNA as a Surveillance Tool for Hepatocellular Carcinoma Patients after Liver Transplant.Cancers · 2023Review
- Ginsenoside Rk3 is a novel PI3K/AKT-targeting therapeutics agent that regulates autophagy and apoptosis in hepatocellular carcinoma.Journal of pharmaceutical analysis · 2023Article
- Effectiveness of lenvatinib plus immune checkpoint inhibitors in primary advanced hepatocellular carcinoma beyond oligometastasis.Clinical and translational medicine · 2023Article
- TRMT6 promotes hepatocellular carcinoma progression through the PI3K/AKT signaling pathway.European journal of medical research · 2023Article
- GCN2 inhibition sensitizes arginine-deprived hepatocellular carcinoma cells to senolytic treatment.Cell metabolism · 2022Article
- Systemic Therapy in Metastatic Hepatocellular Carcinoma.Current gastroenterology reports · 2022Review
- Xihuang pills induce apoptosis in hepatocellular carcinoma by suppressing phosphoinositide 3-kinase/protein kinase-B/mechanistic target of rapamycin pathway.World journal of gastrointestinal oncology · 2022Article
- Weighted gene co-expression network analysis reveals prognostic and diagnostic significance ofJournal of gastrointestinal oncology · 2022Article
- Comprehensive competitive endogenous RNA network analysis revealsIranian journal of basic medical sciences · 2022Article
- Lenvatinib plus anti-PD-1 therapy represents a feasible conversion resection strategy for patients with initially unresectable hepatocellular carcinoma: A retrospective study.Frontiers in oncology · 2022Article
- Advances in Nanoliposomes for the Diagnosis and Treatment of Liver Cancer.International journal of nanomedicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma remains a deadly disease with poor prognosis in patients with unresectable cancer. Trans-arterial chemoembolization is the primary locoregional therapy for intermediate-stage hepatocellular carcinoma, with an estimated median overall survival of less than two years. For almost a decade, sorafenib has been the only standard systemic treatment for metastatic disease or tumors which progress or are considered unsuitable for locoregional therapy. Major breakthroughs have been made over the past few years in the management of hepatocellular carcinoma, especially in medical therapies for advanced disease. In this article, recent advances in intra-arterial therapy, multi-kinase inhibitors, and immunotherapy will be reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.